At Proskope, we are on a mission to transform cancer detection and treatment with our breakthrough innovation. With the alarming increase in cancer cases worldwide and the financial burden associated with their treatment, it is more important than ever to find effective new ways to detect cancer early, when it can be cured.
Our work is the result of joint research efforts by a multidisciplinary team from France and England, with expertise in cancer cell biology and cell imaging software. The test is non-invasive (based on a blood sample), sensitive, quick and cost effective.
Our team is currently focused on designing and manufacturing a fully automated version of the product to confirm its effectiveness through larger scale clinical trials.
If you are passionate about making a difference in the world of healthcare and believe in the power of technology to transform cancer detection and treatment, join us in our mission.
Do not hesitate to contact us to learn more about Proskope!
Company Details
- Founded
- -
- Address
- Paris, Fr
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Paris
Proskope Questions
Proskope's LinkedIn profile is https://fr.linkedin.com/company/proskope
Proskope's industry is
Biotechnology Research
Proskope's top competitors are
Aqemia,
Serendip Innovations,
Brink Therapeutics,
See2cure,
Inhatarget Therapeutics,
Orakl Oncology,
Deuteroncology Nv,
One Biosciences,
Nūmi®,
Let It Care.
Proskope's categories are Biotechnology Research
Proskope's founding year is 2022
